Skip to main content
. 2018 Dec 1;198(11):1423–1434. doi: 10.1164/rccm.201710-2079OC

Figure 5.

Figure 5.

HIF-2α (hypoxia-inducible factor-2α) inhibition reverses severe pulmonary arterial hypertension in Sugen 5416/hypoxia (SuHx) rats. (A) Diagram showing the experimental timeline including C76 (compound 76) treatment in SuHx rats. (B) C76 treatment reduced right ventricular systolic pressure in SuHx rats. (C) Echocardiography measurements showing improvement in pulmonary artery (PA) diastolic function by C76 treatment in SuHx rats. (D–F) Representative images of Russell-Movat pentachrome staining (D) and vascular lesion quantification (E and F) demonstrating inhibited pulmonary vascular remodeling including reduction in occlusive lesions and PA wall thickness in C76-treated SuHx rats. Arrows point to pulmonary vessels with occlusive vascular remodeling. *P < 0.05, **P < 0.01, and ***P < 0.001. (E) Mann-Whitney test. (B, C, and F) One-way ANOVA with Tukey post hoc analysis for multiple group comparisons. (D) Scale bars: 200 μm. mpk = milligrams per kilogram; PA AT/ET = PA acceleration time/ejection time ratio; RVSP = right ventricular systolic pressure; V = vessel.